RecruitingPhase 2NCT07236099

Study of the Efficacy and Safety of ICP-332 in Participants With Prurigo Nodularis

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Efficacy and Safety of ICP-332 in Participants With Prurigo Nodularis

Sponsor

Beijing InnoCare Pharma Tech Co., Ltd.

Enrollment

135 participants

Start Date

Nov 27, 2025

Study Type

INTERVENTIONAL

Conditions

Prurigo Nodularis (PN)

Summary

Evaluate the efficacy and safety of ICP-332 in participants with Prurigo Nodularis (PN)

Eligibility

Min Age: 18 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called ICP-322 and a drug called Placebo for people with prurigo nodularis (pn). The study is currently recruiting participants at 34 locations. People eligible for this study include aged 18 Years to 75 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGICP-322

ICP-322 Tablets

DRUGPlacebo

ICP-332 Placebo Tablets

Locations(43)

Cahaba Dermatology and Skin Health Center

Birmingham, Alabama, United States

Medical Dermatology Specialists

Phoenix, Arizona, United States

Center for Dermatology Clinical Research, Inc.

Fremont, California, United States

Driven Research, LLC

Miami, Florida, United States

Cordova Research Institute

Sweetwater, Florida, United States

Dawes Fretzin Clinical Research Group LLC

Indianapolis, Indiana, United States

Oakland Hills Dermatology

Auburn Hills, Michigan, United States

The Derm Institute of West Michigan

Caledonia, Michigan, United States

Revival Research Institute, LLC

Troy, Michigan, United States

Minnesota Clinical Study Center

New Brighton, Minnesota, United States

Skin Specialists, PC

Omaha, Nebraska, United States

StracSkin, PLLC

Portsmouth, New Hampshire, United States

Apex Clinical Research Center

Mayfield Heights, Ohio, United States

International Clinical Research - Tennessee LLC

Murfreesboro, Tennessee, United States

The Second Affiliated Hospital of Wannan Medical University

Wuhu, Anhui, China

Peking University People's Hospital

Beijing, Beijing Municipality, China

The First Affiliated Hospital of Chongqing Medical University

Chongqing, Chongqing Municipality, China

The First Affiliated Hospital of Fujian Medical University

Fuzhou, Fujian, China

Dermatology Hospital of Southern Medical University

Guangzhou, Guangdong, China

The First Hospital of Hebei Medical University

Shijiazhuang, Hebei, China

Jingzhou Central Hospital

Jingzhou, Hubei, China

Xiangya Hospital of Central South University

Changsha, Hunan, China

The first hospital of Jilin University

Changchun, Jilin, China

Shenyang Seventh People's Hospital

Shenyang, Liaoning, China

Shandong Provincial Dermatology Hospital

Jinan, Shandong, China

Chengdu Second People's Hospital

Chengdu, Sichuan, China

Sichuan Provincial People's Hospital

Chengdu, Sichuan, China

Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital

Tianjin, Tianjin Municipality, China

Affiliated Hangzhou First People's Hospital,School of Medicine ,Westlake University

Hangzhou, Zhejiang, China

Chu de Brest - Hopital Morvan

Brest, France

Uni Berlin Chartie Derma

Berlin, Germany

Rosenpark Research

Darmstadt, Germany

Uni Leipzig Derma

Leipzig, Germany

Dermatologischen Gemeinschaftspraxis Dres. Quist

Mainz, Germany

Specderm Poznanska

Bialystok, Poland

AKK MEDlCAL Spółka z ograniczoną Odpowiedzialnością, Centrum Medyczne Tu się Leczy

Gdansk, Poland

Zdybski Ned SP.Z.O.O

Kielce, Poland

Amicare Centrum Medyczne

Lodz, Poland

Centrum Badawcze Panaceum

Malbork, Poland

Twoja Przychodnia

Nowa Sól, Poland

Twoja Przychodnia Centrum Medyczne

Poznan, Poland

Uniwersytecki Szpital Kliniczny

Rzeszów, Poland

Klinika Ambroziak Dermatologia

Warsaw, Poland

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07236099

Related Trials

Early and Long-Term Efficacy and Immune Changes With Dupilumab in Prurigo Nodularis

NCT072764251 location